LinkedIn
FAQ

VTC Ventures

Investing in early-stage healthcare and high-growth technology companies.

Driving Innovation Through Strategic Investment

Strategic Cornerstones

VTC Ventures is backed by a strategic LP base, forming the foundation of our investment strategy. We leverage strategic affiliations with Carilion Clinic, one of Virginia's premier healthcare systems, and Virginia Tech, a leading research university, to source, diligence, and support exceptional early-stage companies.

Core Tenants

Our approach pairs targeted investment with substantial institutional support, creating a dedicated environment for accelerating innovation. Through close LP alignment, we develop high conviction early in a company's journey, allowing us to build lasting partnerships when they are most impactful. We offer the resources of a large organization with the focus of a small team, providing our founders with direct access to research, pilots, customers, and talent to move from idea to validation.

Accretive Partnership

As financial investors with a strategic mindset, we bridge the gap between market knowledge and investment speed and underwriting. We work closely with our portfolio companies to help them scale and navigate challenges.

Our Approach

We combine strategic capital deployment with institutional resources to help our portfolio companies navigate complexity and build long-term value.

Strategic Affiliations

We leverage our LP relationships to provide founders with more than just capital. By providing strategic access and expertise, we help our portfolio companies accelerate growth from the earliest stages.

Portfolio Company Benefits

Clinical Validation

Direct access to hospital systems, patient populations, and clinical trial infrastructure for rapid market testing and refinement.

Research Excellence

Partnership with cutting-edge university laboratories, engineering talent, and intellectual property resources to accelerate product development.

Operational Insights

Client and end-user derived strategic guidance from healthcare operators and deep tech leaders who understand market needs, workflows, and the complexities of scaling early-stage ventures.

Investment Parameters & Focus Areas

$200K-$1M

Initial Investments

1-3x typically reserved for follow-on

60%

Healthcare

Majority allocation to transformative health innovations

40%

Technology

Strategic investments in high-growth technology sectors

VTC Ventures isn't a generalist fund. Our investment focus is continuously guided by the world-class, ever-evolving subject matter expertise of our LPs. We invest where our LPs provide real, differentiated insight and value. This allows us to identify groundbreaking opportunities at the earliest stages. We take all deal flow seriously and use new investments as opportunities to inspire ideation and market pain point identification and solution validation at the end-user / client level.

Directly aligned with Carilion Clinic's clinical advancements, patient care priorities, and health care transformation.

Driven by Virginia Tech's cutting-edge research in AI, advanced materials, national security, robotics, and complex engineering disciplines.

Informed by Virginia Tech's leadership in agricultural science, food technology, and environmental sustainability research.

Leadership Team

Managed by Middleland Capital, leveraging deep expertise in venture capital, technology commercialization, and operational growth. Our advisory board and management combine scientific, engineering, and business acumen to guide startups from proof-of-concept to market leadership. Direct access to Virginia Tech, FBRI, and Carilion Clinic’s combined talent and expertise.

James Ramey, JD

General Partner

James joined Middleland Capital in 2016 to launch the VTC Innovation Fund and brings nearly 10 years of experience in venture capital and private equity on both the sell- and buy-side. He holds board or observer seats in several companies including Farmer Focus, Earth Optics, CytoRecovery, PlanetIQ, MetiStream, BRAINBox, and others. James earned his J.D. with distinction from the University of Nebraska.

Brian Mixer, MBA

General Partner

Brian joined Middleland Capital in 2009 and has invested in Food & Agtech for the past 15 years. He currently holds board or observer seats in Aerofarms, Arable Labs, Agrivida, Aquaspy, BIOHM Health, Groundwork Bio Ag, Sentera, and Soli Organic. Brian holds a B.A. in Economics from Bucknell University and an MBA from Wharton.

Kody Cobb

Vice President

Kody joined Middleland Capital in 2018 and serves on the board or as an observer for Veracity and Atalan Tech. He earned a B.S. in Chemical Engineering, graduating cum laude from Virginia Tech.

Greg Fisher

Senior Analyst

Greg joined Middleland Capital in 2023. He graduated magna cum laude from Roanoke College with a BBA in Business Administration and a BA in Philosophy.

Healthcare Investment Focus

VTC Ventures specializes in transformative investments within the healthcare sector. Our portfolio emphasizes therapeutic development, innovative medical devices, advanced diagnostics, and cutting-edge health tech solutions. Backed by Virginia Tech, the Fralin Biomedical Research Institute and Carilion Clinic, we provide portfolio companies unrivaled access to development opportunities as early as preclinical trial design, wet lab space and human factors studies and as late as FIH studies, clinical trials, and co-development opportunities using real-world clinical and end user data and workflows.

Therapeutic Development

Supporting next-generation therapeutics as early as lead candidate finalization.

Medical Devices & Diagnostics

Investing in novel devices that improve patient outcomes through innovation in minimally invasive techniques and monitoring technologies.

Healthtech

Advancing technologies that optimize patient care and healthcare operational efficiency.

Featured Healthcare Portfolio Companies

Technology Investment Focus

VTC Ventures drives innovation across deep tech, hard tech, and vertical software with a focus on dual-use defense and artificial intelligence.

Leveraging Virginia Tech’s world-class research in AI, cybersecurity, defense engineering, proximity to our nation's capital, and deep ties across multiple disciplines, we empower portfolio companies with access to specialized labs, expert collaborations, and pioneering technology development. This partnership accelerates breakthrough solutions that address evolving market pain points and emerging threads to deliver mission- and enterprise-critical capabilities.

Advanced Technology Solutions

Robotics, autonomous systems, and sensor innovations

Artificial Intelligence Applications

Machine learning and AI-powered analytics for business and defense intelligence automation and decision support systems.

Cybersecurity Innovations

Next-generation cyber defense technologies protecting critical infrastructure and sensitive information from evolving cyber threats.

Featured Technology Portfolio Companies

Food & Agriculture Investment Focus

VTC Ventures invests in early-stage food and agriculture companies tackling the industry’s most pressing pain points. Our approach targets sectors undergoing structural transformation—where technology can deliver both scalability and defensibility while solving bottlenecks in the global food system. Active advisory by Middleland Capital and Virginia Tech provide our portfolio companies with world-class network access.

Specialty Ingredients

Consumers are demanding new functional, clean-label, and sustainable ingredients. Traditional ingredient development cycles are slow and expensive, creating white space for novel platforms.

Next-Gen Food-as-Medicine

Chronic disease costs are escalating while nutrition remains underutilized as a clinical tool.

Consumer Brands

Legacy food brands are losing share to nimble challengers as consumers demand transparency, sustainability, and health outcomes. There is room for new category leaders with strong brand equity and differentiated supply chains.

Robotics

Labor shortages and rising input costs are putting pressure on production and processing. Robotics and automation offer the potential to lower costs, increase consistency, and solve critical workforce bottlenecks in farming and food manufacturing.

Digitization

Food and agriculture remain under-digitized, with low data interoperability and adoption barriers. We are looking for the platforms of tomorrow that unlock data for decision-making.

Supply Chain Optimization

Agriculture supply chains are fragmented, inefficient, and vulnerable to shocks. Rising input costs, logistics volatility, and waste create demand for solutions that drive efficiency, traceability, and resilience.

We pair deep domain expertise with hands-on partnership to accelerate growth, unlock markets, and drive returns across the global food and ag value chain.

Featured AgTech Portfolio Companies

SW Virginia

We aim to invest in SW Virginia's high performing homegrown companies, and allow companies around the world to access SWVA's talent base

SWVA Companies (Homegrown and regional offices)


Frequently Asked Questions

We've compiled answers to the questions founders and partners ask us most often. VTC Ventures is committed to being a transparent, supportive partner from first pitch to exit — and beyond.

1

Do I need to have a pre-existing connection to the LP base or region to be eligible for investment?

No. We can establish those connections post-investment, and only make such connections when they are accretive to both our investors and our portfolio companies. Our goal is not to recycle capital through the ecosystem without material progress. Once investment is made, we are champions of the company and safeguard its interests in an effort to drive ROI. Without successful companies in the ecosystem, the ecosystem does not benefit. We cannot be successful as an ecosystem, LP base, or investors if our portfolio companies are not winning!

2

Does the fund have geographic restrictions?

No. While many of our companies are based in, or have a regional office in SWVA, many companies are based across the US and the world.

3

Will the fund lead rounds?

Yes, but we are also willing to follow. We have a Switzerland mindset when working with other funds and welcome collaboration. Even if we are not leading a round, we are willing to do the dirty work of helping raise capital for our companies.

4

What instrument is the fund willing to invest in?

Everything from SAFEs to preferred equity.

5

What is the most effective way to meet with us?

Through warm introductions from our network; however, we examine all inbound opportunities regardless of origination.